دورية أكاديمية
أعرض في EDS

Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies

التفاصيل البيبلوغرافية
العنوان: Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies
المؤلفون: Li, Ling, Li, Sheyu, Liu, Jiali, Deng, Ke, Busse, Jason-W., Vandvik, Per-Olav, Wong, Evelyn, Sohani, Zahra-N., Bala, Malgorzata-M., Rios, Lorena-P., Malaga, German, Ebrahim, Shanil, Shen, Jiantong, Zhang, Longhao, Zhao, Pujing, Chen, Qunfei, Wang, Yingqiang, Guyatt, Gordon-H., Sun, Xin
بيانات النشر: BioMed Central
سنة النشر: 2016
المجموعة: Repositorio - UPCH (Universidad Peruana Cayetano Heredia)
مصطلحات موضوعية: Animals, Chi-Square Distribution, Diabetes Mellitus, Type 2/complications/diagnosis/drug therapy/mortality, Glucagon-like peptide-1 receptor, Glucagon-Like Peptide-1 Receptor/agonists/metabolism, Heart failure, Heart Failure/diagnosis/etiology/mortality, Hospitalization, Humans, Hypoglycemic Agents/adverse effects/therapeutic use, Meta-analysis, Observational Studies as Topic, Odds Ratio, Randomized Controlled Trials as Topic, Risk Assessment, Risk Factors, Systematic review, Time Factors, Treatment Outcome, Type 2 diabetes, https://purl.org/pe-repo/ocde/ford#3.02.00Test, https://purl.org/pe-repo/ocde/ford#1.06.07Test
الوصف: BACKGROUND: The effect of glucagon-like peptide-1(GLP-1) receptor agonists on heart failure remains uncertain. We therefore conducted a systematic review to assess the possible impact of GLP-1 agonists on heart failure or hospitalization for heart failure in patients with type 2 diabetes. METHODS: We searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL) and ClinicalTrials.gov to identify randomized controlled trials (RCTs) and observational studies that addressed the effect of GLP-1 receptor agonists in adults with type 2 diabetes, and explicitly reported heart failure or hospitalization for heart failure. Two paired reviewers screened reports, collected data, and assessed the risk of bias. We pooled data from RCTs and observational studies separately, and used the GRADE approach to rate the quality of evidence. RESULTS: We identified 25 studies that were eligible for our review; 21 RCTs (n = 18,270) and 4 observational studies (n = 111,029). Low quality evidence from 20 RCTs suggested, if anything, a lower incidence of heart failure between GLP-1 agonists versus control (17/7,441 vs. 19/4,317; odds ratio (OR) 0.62, 95 % confidence interval (CI) 0.31 to 1.22; risk difference (RD) 19 fewer, 95 % CI 34 fewer to 11 more per 1000 over 5 years). Three cohort studies comparing GLP-1 agonists to alternative agents provided very low quality evidence that GLP-1 agonists do not increase the incidence of heart failure. One RCT provided moderate quality evidence that GLP-1 agonists were not associated with hospitalization for heart failure (lixisenatide vs placebo: 122/3,034 vs. 127/3,034; adjusted hazard ratio 0.96, 95 % CI 0.75 to 1.23; RD 4 fewer, 95 % CI 25 fewer to 23 more per 1000 over 5 years) and a case-control study provided very low quality evidence also suggesting no association (GLP-1 agonists vs. other anti-hyperglycemic drugs: 1118 cases and 17,626 controls, adjusted OR 0.67, 95 % CI 0.32 to 1.42). CONCLUSIONS: The current evidence suggests that GLP-1 agonists do not increase ...
نوع الوثيقة: article in journal/newspaper
اللغة: English
تدمد: 1471-2164
العلاقة: urn:issn:1471-2164; https://hdl.handle.net/20.500.12866/5101Test; https://doi.org/10.1186/s12872-016-0260-0Test
DOI: 10.1186/s12872-016-0260-0
الإتاحة: https://doi.org/20.500.12866/5101Test
https://doi.org/10.1186/s12872-016-0260-0Test
https://hdl.handle.net/20.500.12866/5101Test
حقوق: info:eu-repo/semantics/restrictedAccess ; https://creativecommons.org/licenses/by-nc-nd/4.0/deed.esTest
رقم الانضمام: edsbas.882C793
قاعدة البيانات: BASE
الوصف
تدمد:14712164
DOI:10.1186/s12872-016-0260-0